ArticlePloS one2017
Anti-cancer stem cell activity of a sesquiterpene lactone isolated from Ambrosia arborescens and of a synthetic derivative.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Siwa spring microbiomes as reservoirs of biosynthetic gene clusters: Unlocking natural product potential.World journal of microbiology & biotechnology · 2026Article
- Chemical Composition and Preliminary Screening of Anticholinesterase and Antioxidant Activities of the Essential Oil ofPlants (Basel, Switzerland) · 2026Article
- In Silico and In Vitro Evaluation of δ-cadinene fromCancers · 2025Article
- Sesquiterpene Lactones as Promising Phytochemicals to Cease Metastatic Propagation of Cancer.Biomolecules · 2025Review
- Microwave-Assisted Extraction of Secondary Metabolites Using Ethyl Lactate Green Solvent fromPlants (Basel, Switzerland) · 2024Article
- Effect ofVeterinary world · 2024Article
- A new animal product free defined medium for 2D and 3D culturing of normal and cancer cells to study cell proliferation and migration as well as dose response to chemical treatment.Toxicology reports · 2023Article
- Antiproliferative and cytotoxic effects of sesquiterpene lactones isolated fromPharmaceutical biology · 2022Article
- A comprehensive phytochemical and pharmacological review on sesquiterpenes from the genusHeliyon · 2022Review
- Poorly Investigated Ecuadorian Medicinal Plants.Plants (Basel, Switzerland) · 2022Review
- Acute toxicity of aqueous extract ofToxicological research · 2022Article
- Expanding the Study of the Cytotoxicity of Incomptines A and B against Leukemia Cells.Molecules (Basel, Switzerland) · 2022Article
- Article
- Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones.Molecules (Basel, Switzerland) · 2022Review
- Cytotoxic and other bioactivities of a novel and known sesquiterpene lactones isolated fromToxicology reports · 2022Article
- Cytotoxicity and molecular docking analysis of racemolactone I, a new sesquiterpene lactone isolated fromPharmaceutical biology · 2021Article
- Breast cancer cell line toxicity of a flavonoid isolated from Baccharis densiflora.BMC complementary medicine and therapies · 2021Article
- Function-Oriented and Modular (+/-)-cis-Pseudoguaianolide Synthesis: Discovery of New Nrf2 Activators and NF-κB Inhibitors.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- A novel 3D polycaprolactone high-throughput system for evaluation of toxicity in normoxia and hypoxia.Toxicology reports · 2021Article
- Suppressive role of Viola odorata extract on malignant characters of mammosphere-derived breast cancer stem cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New regimens are constantly being pursued in cancer treatment, especially in the context of treatment-resistant cancer stem cells (CSCs) that are assumed to be involved in cancer recurrence. Here, we investigated the anti-cancer activity of sesquiterpene lactones (SLs) isolated from Ambrosia arborescens and of synthetic derivatives in breast cancer cell lines, with a specific focus on activity against CSCs. The breast cancer cell lines MCF-7, JIMT-1, and HCC1937 and the normal-like breast epithelial cell line MCF-10A were treated with the SLs damsin and coronopilin, isolated from A. arborescens, and with ambrosin and dindol-01, synthesized using damsin. Inhibitory concentration 50 (IC50) values were obtained from dose-response curves. Based on IC50 values, doses in the μM range were used for investigating effects on cell proliferation, cell cycle phase distribution, cell death, micronuclei formation, and cell migration. Western blot analysis was used to investigate proteins involved in cell cycle regulation as well as in the NF-κB pathway since SLs have been shown to inhibit this transcription factor. Specific CSC effects were investigated using three CSC assays. All compounds inhibited cell proliferation; however, damsin and ambrosin were toxic at single-digit micromolar ranges, while higher concentrations were required for coronopilin and dindol-01. Of the four cell lines, the compounds had the least effect on the normal-like MCF-10A cells. The inhibition of cell proliferation can partly be explained by downregulation of cyclin-dependent kinase 2. All compounds inhibited tumour necrosis factor-α-induced translocation of NF-κB from the cytoplasm to the nucleus. Damsin and ambrosin treatment increased the number of micronuclei; moreover, another sign of DNA damage was the increased level of p53. Treatment with damsin and ambrosin decreased the CSC subpopulation and inhibited cell migration. Our results suggest that these compounds should be further investigated to find efficient CSC-inhibiting compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.